{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:56:29Z","timestamp":1791276989733,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["10SDG 3030051"],"award-info":[{"award-number":["10SDG 3030051"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009238","name":"Virginia Commonwealth University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.amjcard.2014.11.003","type":"journal-article","created":{"date-parts":[[2014,11,16]],"date-time":"2014-11-16T15:55:12Z","timestamp":1416153312000},"page":"288-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies)"],"prefix":"10.1016","volume":"115","clinical-trial-number":[{"clinical-trial-number":"nct00789724","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01175018","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Antonio","family":"Abbate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Christopher","family":"Kontos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayef Antar","family":"Abouzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan David","family":"Melchior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Wallace","family":"Van Tassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Oddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory Ross","family":"Trankle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Susan","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Herman","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Lucas","family":"Gambill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanah","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshanak","family":"Markley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Wayne","family":"Vetrovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Anthony","family":"Dinarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Biondi-Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2014.11.003_bib1","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1093\/eurheartj\/eht435","article-title":"Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association of the European Society of Cardiology. How to use C-reactive protein in acute coronary care","volume":"34","author":"Biasucci","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2014.11.003_bib2","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.jacc.2014.01.014","article-title":"Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction","volume":"63","author":"Seropian","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2014.11.003_bib3","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.amjcard.2014.11.003_bib4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/CIRCULATIONAHA.113.003199","article-title":"Targeting interleukin-1 in heart disease","volume":"128","author":"Van Tassell","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2014.11.003_bib5","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.amjcard.2009.12.059","article-title":"Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)","volume":"105","author":"Abbate","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2014.11.003_bib6","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]","volume":"111","author":"Abbate","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2014.11.003_bib7","article-title":"The effect of Interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","author":"Morton","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2014.11.003_bib8","doi-asserted-by":"crossref","first-page":"e33438","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced Interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2014.11.003_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2014.11.003_bib10","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"CANTOS Pilot Investigative Group. Effects of Interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2014.11.003_bib11","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2337\/dc11-2219","article-title":"Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes","volume":"35","author":"Cavelti-Weder","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2014.11.003_bib12","article-title":"Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?","author":"Abbate","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2014.11.003_bib13","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2014.11.003_bib14","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCOUTCOMES.112.966150","article-title":"Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward","volume":"5","author":"Eapen","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjcard.2014.11.003_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/s-2004-815695","article-title":"C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes","volume":"3","author":"Abbate","year":"2003","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.amjcard.2014.11.003_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-6215-9-8","article-title":"Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)","volume":"9","author":"Crossman","year":"2008","journal-title":"Trials"},{"key":"10.1016\/j.amjcard.2014.11.003_bib17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2014.11.003_bib18","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction","volume":"117","author":"Abbate","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2014.11.003_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00011-013-0625-0","article-title":"Interleukin-1\u03b2 induces a reversible cardiomyopathy in the mouse","volume":"62","author":"Van Tassell","year":"2013","journal-title":"Inflamm Res"},{"key":"10.1016\/j.amjcard.2014.11.003_bib20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1113\/expphysiol.2012.069831","article-title":"Interleukin-1\u03b2 blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse","volume":"98","author":"Toldo","year":"2013","journal-title":"Exp Physiol"},{"key":"10.1016\/j.amjcard.2014.11.003_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000106","article-title":"Interleukin-1\u03b2 blockade improves left ventricular systolic\/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse","volume":"64","author":"Toldo","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2014.11.003_bib22","unstructured":"VCU-ART3. Available at: www.clinicaltrials.gov\/show\/NCT01950299. Accessed September 26,\u00a02014."},{"key":"10.1016\/j.amjcard.2014.11.003_bib23","unstructured":"CANTOS HF, substudy. Available at: www.clinicaltrials.gov\/show\/NCT01900600. Accessed September 26,\u00a02014."},{"key":"10.1016\/j.amjcard.2014.11.003_bib24","article-title":"Targeting interleukin-1 in heart failure and inflammatory heart disease","author":"Van Tassell","year":"2014","journal-title":"Curr Heart Fail Rep"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914914020724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914914020724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:03:58Z","timestamp":1762077838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914914020724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0002914914020724"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2014.11.003","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2014.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}